Conjugated estrogens
- Generic Name
- Conjugated estrogens
- Brand Names
- Congest, Duavee, Duavive, Premarin, Premphase 28 Day, Prempro 0.625/2.5 28 Day
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 12126-59-9
- Unique Ingredient Identifier
- IU5QR144QX
- Background
The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.
...
- Indication
The conjugated estrogens are indicated for several different conditions including:
- Associated Conditions
- Abnormal Uterine Bleeding, Atrophic Vaginitis, Atrophy of vulva, Kraurosis Vulvae, Menopause, Metastatic Breast Cancer, Moderate to Severe Vasomotor Symptoms, Osteoporosis, Androgen-dependent tumor Advanced Prostate Carcinoma, Hypoestrogenism, Moderate Dyspareunia, Moderate Vulvar and Vaginal Atrophy, Severe Dyspareunia, Severe Vulvar and Vaginal Atrophy
- Associated Therapies
- Estrogen Replacement Therapy, Palliative Treatment
Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Registration Number
- NCT02860897
- Locations
- 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT02729701
- Locations
- 🇺🇸
University of Kansas Medical Center Breast Cancer Prevention Center, Westwood, Kansas, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01778985
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Premarin Versus Toviaz for Treatment of Overactive Bladder
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 90
- Registration Number
- NCT01613170
- Locations
- 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
- Conditions
- Interventions
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Warner Chilcott
- Target Recruit Count
- 249
- Registration Number
- NCT01070979
- Locations
- 🇺🇸
Warner Chilcott Investigational Site, Tacoma, Washington, United States
Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT01023178
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study Evaluating Premarin and Bazedoxifene Potential Interaction
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00745173
- Locations
- 🇺🇸
Dr. David Carter, Austin, Texas, United States
Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)
- Conditions
- Interventions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 356
- Registration Number
- NCT00604825
- Locations
- 🇬🇧
GSK Investigational Site, Waterloo, Liverpool, United Kingdom
Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2006-09-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT00380887
Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array
- Conditions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00318318
- Locations
- 🇨🇦
Lawson Health Research Institute, London, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.